Previous Close | 9.39 |
Open | 9.47 |
Bid | 9.54 x 0 |
Ask | 9.55 x 0 |
Day's Range | 9.45 - 9.67 |
52 Week Range | 9.45 - 9.67 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
(Bloomberg) -- A well-publicized short bet by General Industrial Partners on Spanish company Grifols SA helped the hedge fund earn double-digit gains while bullish wagers on the same stock caused losses to former Elliott Management trader Franck Tuil.Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio Closings‘Seriously Underwater’ Home Mortgages Tick Up Across the USAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackMarjorie Taylor Greene Finally Got Wha
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.